Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds - Takeaways - MDSpire

Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

  • By

  • Shaima Wasim Khan

  • Noorah Al Hosani

  • Thaer Khaleel Swaid

  • Mazin M Edan

  • Mohammed Nabil Quraishi

  • June 26, 2026

  • 0 min

Share

  • 1

    In a cohort of 248 patients with inflammatory bowel disease, immunogenicity developed in 28.3% of 314 anti-TNF treatment courses.

  • 2

    Infliximab and adalimumab had comparable immunogenicity rates of 26.9% and 31.4%, respectively, with immunogenicity-mediated failure as the leading cause of discontinuation.

  • 3

    Pre-event trough levels were significantly lower in immunogenic courses, with median levels of 3.0 mcg/mL compared to 14.0 mcg/mL in non-immunogenic courses.

  • 4

    Exploratory thresholds for predicting immunogenicity were identified at 5.3 mcg/mL for infliximab and 6.4 mcg/mL for adalimumab, showing high discriminative accuracy.

  • 5

    Subcutaneous infliximab demonstrated lower immunogenicity compared to intravenous infliximab, suggesting a potential immunogenic advantage.

Original Source(s)

Anti-TNF immunogenicity in a Middle Eastern inflammatory bowel disease cohort: prevalence, predictors and context-specific drug level thresholds

  • by Shaima Wasim Khan, Noorah Al Hosani, Thaer Khaleel Swaid, Mazin M Edan, Mohammed Nabil Quraishi

  • June 26, 2026

Related Content

Microbiota metabolite butyrate alleviates intestinal inflammation associated with enhanced autophagy-related signaling in DSS-induced colitis

The role of Astragalus membranaceus and its derivatives in digestive system diseases: reconstruction of immune tolerance

Nurr1 deficiency orchestrates a coupled liver–gut pathological axis revealed by multi-omics and deep-learning histopathology